Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCAINAMIDE HCL vs NORPACE CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.
Class Ia antiarrhythmic agent; decreases myocardial excitability and conduction velocity, and prolongs refractory period by blocking sodium channels.
Treatment of documented ventricular arrhythmias (e.g., sustained ventricular tachycardia) that are life-threatening,Off-label: Atrial fibrillation, atrial flutter, supraventricular tachycardia, Wolff-Parkinson-White syndrome
Treatment of documented life-threatening ventricular arrhythmias (e.g., sustained ventricular tachycardia),Off-label: prevention of atrial fibrillation recurrence, maintenance of sinus rhythm in atrial flutter
For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.
Disopyramide controlled-release: 200 mg orally every 12 hours; maximum 400 mg/day.
Terminal elimination half-life: 2.5-4.7 hours (3 hours typical) in normal renal function; prolonged to 11-20 hours in renal impairment; NAPA half-life 6-8 hours (prolonged in renal failure).
Terminal elimination half-life: 6-12 hours (normal renal function); prolonged to 12-20 hours in renal impairment. In coronary artery disease, half-life may be extended due to reduced clearance.
Hepatic via N-acetyltransferase (NAT2) to N-acetylprocainamide (NAPA); also undergoes hydrolysis to p-aminobenzoic acid.
Primarily hepatic via CYP3A4; also excreted renally.
Primarily renal (50-60% unchanged via glomerular filtration and tubular secretion) with 10-30% as N-acetylprocainamide (NAPA) metabolite; minor biliary/fecal (<5%).
Renal (50-57% unchanged), hepatic metabolism (30-40%), fecal (<10%). Dose adjustment required for Cr Cl <40 m L/min.
15-25% bound primarily to alpha-1-acid glycoprotein and albumin.
30-50% bound to albumin, alpha-1-acid glycoprotein, and lipoproteins.
1.5-2.5 L/kg (approximates total body water; indicates extensive tissue distribution).
0.6-1.2 L/kg; larger Vd in heart failure (up to 2.0 L/kg) due to reduced tissue binding.
Oral: 75-95% (immediate-release); IM: 100%; IV: 100%.
Oral immediate-release: 70-80%; extended-release: 60-70% (first-pass metabolism). IV: 100%.
Cr Cl >50 m L/min: No adjustment. Cr Cl 10-50 m L/min: Administer every 6-12 hours. Cr Cl <10 m L/min: Administer every 12-24 hours.
GFR 30-50 m L/min: 200 mg loading dose, then 100 mg every 12 hours. GFR 15-30 m L/min: 200 mg loading dose, then 100 mg every 24 hours. GFR <15 m L/min: 200 mg loading dose, then 100 mg every 48-72 hours.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50%. Child-Pugh Class C: Reduce dose by 50-75% or avoid use.
Child-Pugh Class B or C: Reduce dose by 50% and titrate carefully; monitor ECGs.
IV: Loading dose: 15 mg/kg over 30-60 minutes, followed by maintenance infusion of 20-80 mcg/kg/min; maximum 2 g/day. Oral: 15-50 mg/kg/day in divided doses every 3-6 hours; maximum 4 g/day.
Not recommended for pediatric use; safety and efficacy not established.
Start at lower end of dosing range due to age-related decreased renal function and increased risk of hypotension and arrhythmias. Monitor renal function and adjust accordingly.
Initiate at lower dose (e.g., 100 mg every 12 hours of controlled-release) due to increased risk of anticholinergic effects and renal impairment; monitor renal function and QT interval.
Procanamide can cause agranulocytosis, leukopenia, and thrombocytopenia; fatal blood dyscrasias have occurred. Frequent blood counts are recommended.
May cause widening of QRS complex and prolongation of QT interval, increasing risk of torsade de pointes and sudden death. Avoid use with other drugs that prolong QT interval. Use only for life-threatening arrhythmias.
May cause lupus erythematosus-like syndrome (especially with slow acetylator phenotype); proarrhythmic effects (torsades de pointes); hypotension; bone marrow suppression; hepatotoxicity; potentiation of neuromuscular blocking agents.
Can worsen arrhythmias (proarrhythmic); monitor ECG, electrolytes; adjust dose in renal/hepatic impairment; avoid in patients with pre-existing QT prolongation, hypokalemia, or bradycardia.
Complete heart block; second- or third-degree AV block without pacemaker; long QT syndrome; torsades de pointes; known hypersensitivity to procainamide or any component.
Pre-existing second- or third-degree AV block (unless pacemaker), cardiogenic shock, congenital QT prolongation, concurrent use of other QT-prolonging drugs, hypersensitivity to disopyramide.
No significant food interactions reported. However, changes in dietary salt intake may affect blood pressure control; avoid excessive caffeine or alcohol as they may trigger arrhythmias. Maintain consistent potassium and magnesium intake; severe electrolyte disbalances can alter drug effect.
Avoid grapefruit juice as it may increase disopyramide levels. High-fat meals may delay absorption but do not significantly affect overall bioavailability; take consistently with or without food.
FDA pregnancy category C. Procainamide crosses the placenta. In first trimester, risk of congenital anomalies is not well-studied; animal studies show no teratogenicity but use only if clearly needed. In second and third trimesters, chronic use may be associated with fetal bradycardia, QT prolongation, and neonatal lupus syndrome (transient). Avoid in pregnancy if possible.
FDA Pregnancy Category C. First trimester: Evidence of teratogenicity in animal studies (increased fetal resorption and skeletal abnormalities) but no adequate human studies. Second and third trimesters: May cause fetal bradycardia, hypoglycemia, and preterm labor due to beta-blockade effects; avoid use unless benefit outweighs risk.
Procainamide and its active metabolite NAPA are excreted into breast milk. Milk-to-plasma ratio is approximately 0.8-1.3. Concentrations in milk can reach therapeutic levels. Potential for adverse effects in nursing infant, including bradycardia and hypotension. Use with caution, monitor infant. AAP recommends avoiding use if possible.
Disopyramide is excreted in human breast milk; M/P ratio approximately 0.5-1.0. Limited data suggests low infant exposure but potential for hypoglycemia and bradycardia; caution advised. American Academy of Pediatrics considers disopyramide compatible with breastfeeding with monitoring.
Pregnancy alters pharmacokinetics: increased volume of distribution may require higher loading doses (25-30% increase). Decreased plasma albumin reduces protein binding, increasing free fraction. Enhanced renal clearance (due to increased GFR) may necessitate more frequent dosing or dose adjustments. Monitor serum concentrations closely. Start with oral doses of 50 mg/kg/day in divided doses, titrate to effect. Intravenous: initial 100 mg every 5 minutes until arrhythmia controlled, then maintenance 2-6 mg/min with adjustments.
No formal dosing guidelines established. Pregnancy may alter pharmacokinetics (increased volume of distribution and clearance), potentially requiring dose adjustments. Therapeutic drug monitoring is recommended to maintain trough disopyramide levels between 2-5 mcg/m L. Due to proarrhythmic risks, use lowest effective dose and monitor closely.
Procainamide HCL is a Class IA antiarrhythmic used for atrial and ventricular arrhythmias. It can cause lupus-like syndrome, especially in slow acetylators; monitor ANA titers. Renal dose adjustment is critical due to active metabolite N-acetylprocainamide (NAPA) accumulation. Watch for QT prolongation and torsades de pointes; avoid with other QT-prolonging drugs. Administer IV slowly to avoid hypotension; oral loading requires hepatic first-pass consideration.
NORPACE CR (disopyramide phosphate) is a Class Ia antiarrhythmic with strong anticholinergic effects; monitor for urinary retention, constipation, and dry mouth. It has negative inotropic effects and should be avoided in patients with compensated heart failure or cardiomyopathy. Dosage adjustment required in renal impairment (Cr Cl <40 m L/min). Therapeutic drug monitoring recommended (target 2-5 mcg/m L).
Take this medication exactly as prescribed; do not double doses if missed.,Report any symptoms of lupus (joint pain, rash, fever, chest pain) immediately.,Avoid sudden position changes to prevent dizziness from low blood pressure.,Tell your doctor all other medications, especially other heart rhythm drugs.,You may need regular blood tests to monitor drug levels and organ function.,Do not stop taking this medicine abruptly; sudden stop may worsen arrhythmia.,If using extended-release tablets, do not crush or chew them.
Do not crush or chew extended-release tablets; swallow whole.,Take at regular 12-hour intervals to maintain steady drug levels.,Avoid driving or operating machinery until you know how this medication affects you (may cause dizziness or blurred vision).,Report signs of hypoglycemia (sweating, shakiness) in diabetic patients, as disopyramide can lower blood sugar.,Maintain adequate fluid intake to prevent constipation.,Inform all healthcare providers you are taking this medication, especially before surgery or dental procedures.
"Procainamide is a class IA antiarrhythmic that is primarily metabolized by N-acetyltransferase (NAT) and also undergoes CYP2D6-mediated metabolism. Midostaurin, a multikinase inhibitor used for FLT3-mutated AML, is metabolized mainly by CYP3A4. Procainamide can inhibit CYP3A4, reducing the clearance and increasing plasma concentrations of midostaurin, potentially leading to enhanced toxicity including QT prolongation, hepatotoxicity, and myelosuppression."
"Procainamide, a Class Ia antiarrhythmic, prolongs the QT interval by blocking cardiac sodium channels and delaying repolarization. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has been associated with QT prolongation, possibly via inhibition of cardiac hERG potassium channels. Concomitant use increases the risk of excessive QT prolongation, potentially leading to torsade de pointes and other ventricular arrhythmias."
"Procainamide, a class Ia antiarrhythmic agent, prolongs the QT interval by blocking cardiac sodium and potassium channels. Pentamidine, used for Pneumocystis pneumonia, also prolongs the QT interval through inhibition of the rapid delayed rectifier potassium current (IKr). Concomitant use can cause additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with electrolyte disturbances or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCAINAMIDE HCL vs NORPACE CR, answered by our medical review team.
PROCAINAMIDE HCL is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.. NORPACE CR is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; decreases myocardial excitability and conduction velocity, and prolongs refractory period by blocking sodium channels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCAINAMIDE HCL and NORPACE CR depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCAINAMIDE HCL is: For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.. The standard adult dose of NORPACE CR is: Disopyramide controlled-release: 200 mg orally every 12 hours; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCAINAMIDE HCL and NORPACE CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCAINAMIDE HCL is classified as Category A/B. FDA pregnancy category C. Procainamide crosses the placenta. In first trimester, risk of congenital anomalies is not well-studied; animal studies show no teratogenicity but use onl. NORPACE CR is classified as Category C. FDA Pregnancy Category C. First trimester: Evidence of teratogenicity in animal studies (increased fetal resorption and skeletal abnormalities) but no adequate human studies. Secon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.